BSE: 544319 | NSE: SENORES | Pharmaceuticals & Drugs |
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation Index Colour Code Guide ⓘ
| Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|
| ROCE % ⓘ | 2.9% | 5.5% | 2.6% | - |
| Value Creation Index ⓘ | -0.8 | -0.6 | -0.8 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | ||||
| Sales ⓘ | 13.5 | 12.4 | 34 | 34 |
| Sales YoY Gr. | - | -8.6% | 174.7% | - |
| Adj EPS ⓘ | 0.6 | -1.2 | 0.1 | 0.2 |
| YoY Gr. | - | -314% | NA | - |
| BVPS (₹) ⓘ | 38.5 | 39.7 | 55.1 | 176.7 |
| Adj Net Profit ⓘ | 0.5 | -1.2 | 0.4 | 1 |
| Cash Flow from Ops. ⓘ | -24.1 | -43.4 | -62.8 | - |
| Debt/CF from Ops. ⓘ | -0.6 | -1.4 | -1.5 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | NA | 174.7% | ||||
| Adj EPS ⓘ | NA | NA | NA | NA | ||||
| BVPSⓘ | NA | NA | NA | 39% | ||||
| Share Price | - | - | - | - | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|
| Return on Equity % ⓘ | 1.5 | -3.3 | 0.4 | 0.2 |
| Op. Profit Mgn % ⓘ | 8.5 | -14.4 | -0.2 | -15.9 |
| Net Profit Mgn % ⓘ | 3.7 | -9.7 | 1.1 | 2.4 |
| Debt to Equity ⓘ | 0.4 | 1.6 | 0.6 | - |
| Working Cap Days ⓘ | 0 | 1,783 | 1,262 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 311 | 157 | 0 |
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 0.2 | 6.8 |
| TTM Sales (₹ Cr.) | 34 | 215 |
| BVPS (₹.) ⓘ | 176.7 | 187.9 |
| Reserves (₹ Cr.) ⓘ | 768 | 819 |
| P/BV ⓘ | 3.26 | 3.07 |
| PE ⓘ | 0.00 | 84.45 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 440.00 / 664.00 |
| All Time Low / High (₹) | 440.00 / 664.00 |
| Market Cap (₹ Cr.) | 2,656 |
| Equity (₹ Cr.) | 46.1 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 39.6 |
| Mar'24 | YoY Gr. Rt. % | Jun'24 | YoY Gr. Rt. % | Sep'24 | YoY Gr. Rt. % | Dec'24 | YoY Gr. Rt. % | |
|---|---|---|---|---|---|---|---|---|
| Sales (₹ Cr.)ⓘ | 33.4 | -6.6 | 35.3 | -7.6 | 41.5 | 19.3 | 46.8 | 15.7 |
| Adj EPS (₹) ⓘ | 0.8 | -43.9 | 0.9 | -29.8 | 1.6 | 53.5 | 1.8 | 45.9 |
| Op. Profit Mgn % ⓘ | 13.85 | -577 bps | 14.64 | -291 bps | 20.55 | 495 bps | 21.51 | 310 bps |
| Net Profit Mgn % ⓘ | 8.07 | -528 bps | 8.31 | -261 bps | 12.79 | 284 bps | 13.07 | 271 bps |
| Pledged * | 0.00 | 0.00 |
| Company Name | CMP(₹) | |||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharma Inds. | 1,770.1 | 55.9 (3.3%) | Large Cap | 48,497 | 47.7 | 20.9 | 37.2 | 5.9 |
| Dr. Reddys Lab | 1,151.3 | 1.5 (0.1%) | Large Cap | 28,011 | 64.4 | 19.6 | 17.9 | 3 |
| Cipla | 1,495.2 | 42.5 (2.9%) | Large Cap | 25,774 | 61.8 | 15.6 | 24.2 | 4 |
| Lupin | 2,094.5 | 85.1 (4.2%) | Mid Cap | 20,011 | 62.8 | 9.7 | 33.3 | 5.8 |
| Zydus Lifesciences | 901.1 | 9.8 (1.1%) | Large Cap | 19,547 | 45.1 | 19.3 | 20 | 4 |
| Glenmark Pharma | 1,542.9 | 26.6 (1.8%) | Mid Cap | 11,813 | -6.2 | -10.2 | - | 5 |
| Torrent Pharma | 3,249.8 | 40.5 (1.3%) | Large Cap | 10,728 | 55 | 14.8 | 59.1 | 13.7 |
| Aurobindo Pharma | 1,176.1 | 17.4 (1.5%) | Mid Cap | 10,646 | 33 | 17.2 | 35.6 | 3.4 |
| Alkem Laboratories | 4,939.1 | 47.9 (1%) | Mid Cap | 9,748 | 190.9 | 18.1 | 26 | 4.8 |
| Mankind Pharma | 2,435.9 | 14.8 (0.6%) | Mid Cap | 9,265 | 47.4 | 19.6 | 51.2 | 7.1 |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|
| Sales | 14 | 12 | 34 |
| Operating Expenses ⓘ | 12 | 14 | 34 |
| Manufacturing Costs | 0 | 0 | 1 |
| Material Costs | 8 | 6 | 19 |
| Employee Cost | 3 | 5 | 9 |
| Other Costs ⓘ | 1 | 3 | 4 |
| Operating Profit ⓘ | 1 | -2 | 0 |
| Operating Profit Margin (%) | 8.5% | -14.4% | -0.2% |
| Other Income ⓘ | 1 | 7 | 7 |
| Interest ⓘ | 1 | 2 | 3 |
| Depreciation ⓘ | 1 | 1 | 2 |
| Exceptional Items ⓘ | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 1 | 2 | 2 |
| Tax ⓘ | 0 | 1 | 1 |
| Profit After Tax | 1 | 1 | 1 |
| PAT Margin (%) | 5.0% | 9.7% | 2.4% |
| Adjusted EPS (₹) | 0.8 | 1.2 | 0.3 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 34 | 39 | 168 | |||||||
| Share Capital ⓘ | 9 | 10 | 31 | |||||||
| Reserves ⓘ | 25 | 29 | 138 | |||||||
| Minority Interest | 0 | 0 | 0 | |||||||
| Debt | 14 | 32 | 28 | |||||||
| Long Term Debt | 12 | 24 | 20 | |||||||
| Short Term Debt | 2 | 8 | 8 | |||||||
| Trade Payables | 6 | 4 | 12 | |||||||
| Others Liabilities ⓘ | 1 | 36 | 78 | |||||||
| Total Liabilities ⓘ | 55 | 112 | 286 | |||||||
Fixed Assets | ||||||||||
| Gross Block | 3 | 10 | 28 | |||||||
| Accumulated Depreciation | 1 | 2 | 4 | |||||||
| Net Fixed Assetsⓘ | 2 | 8 | 24 | |||||||
| CWIP ⓘ | 3 | 11 | 18 | |||||||
| Investmentsⓘ | 12 | 8 | 82 | |||||||
| Inventories | 3 | 3 | 5 | |||||||
| Trade Receivables | 8 | 16 | 22 | |||||||
| Cash Equivalents | 1 | 0 | 10 | |||||||
| Others Assetsⓘ | 26 | 65 | 125 | |||||||
| Total Assets ⓘ | 55 | 112 | 286 | |||||||
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -24 | -43 | -63 |
| PBT ⓘ | 1 | 2 | 2 |
| Adjustment ⓘ | 1 | -2 | -3 |
| Changes in Working Capital ⓘ | -25 | -43 | -61 |
| Tax Paid ⓘ | 0 | 0 | -1 |
| Cash Flow From Investing Activity ⓘ | -10 | -5 | -14 |
| Capex | 0 | -8 | -19 |
| Net Investments | 0 | 0 | 0 |
| Others ⓘ | -10 | 3 | 6 |
| Cash Flow From Financing Activityⓘ | 34 | 47 | 87 |
| Net Proceeds from Shares ⓘ | 24 | 3 | 37 |
| Net Proceeds from Borrowing ⓘ | 9 | 13 | 16 |
| Interest Paid ⓘ | -1 | -2 | -3 |
| Dividend Paid ⓘ | 0 | 0 | 0 |
| Others ⓘ | 1 | 33 | 37 |
| Net Cash Flow ⓘ | 0 | -2 | 10 |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 2.02 | 3.3 | 0.79 | |||||||
| ROCE (%) | 2.9 | 5.54 | 2.64 | |||||||
| Asset Turnover Ratio | 0.25 | 0.15 | 0.17 | |||||||
| PAT to CFO Conversion(x) | -24 | -43 | -63 | |||||||
| Working Capital Days | ||||||||||
| Receivable Days | 226 | 355 | 203 | |||||||
| Inventory Days | 80 | 90 | 41 | |||||||
| Payable Days | 269 | 325 | 151 | |||||||
Senores Pharmaceuticals Limited was originally incorporated as ‘Senores Pharmaceuticals Private Limited’ under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. The name of the Company was thereafter changed to ‘Senores Pharmaceuticals Limited’ upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023, a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.
Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing it as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, it strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
It leverages its R&D capabilities to develop and manufacture a portfolio of differentiated complex pharmaceutical products. Its focus on quality and its ability to identify specialty and complex molecules has resulted in a pipeline of curated complex products spanning diverse dosage forms and therapeutic domains, demonstrated through its partnerships in the Regulated Markets of US, Canada and United Kingdom with foreign and Indian pharmaceutical companies.
Products of the company
Marketed Products
ANDA Products
Sourced Products
Awards, accreditations and recognitions
History and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
100% Secure Process
Account Discovery
- OTP from CAMS
Account Linking for Stocks & MF
- One OTP per link Eg. NSDL, CDSL, CAMS, KFin etc.
One Click Upload for your Current Portfolio and Future Transactions!
Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
